Biotechs must now adopt new commercial models if breakthrough treatments are to reach the patients they’re designed to help.
Sanofi's new R&D chief said on Wednesday Western drugmakers cannot ignore China's accelerating innovation and should consider ...
Hold: $1.2bn Zealand obesity deal, GB-0895 Phase 3 asthma readout vs Tezspire, cash burn risks, AI platform optionality—read ...
While industry leaders are unsure whether the U.S. or China will prevail, they are largely united in the belief that Europe ...
A two-year partnership with Ultrahuman aims to connect clinical biomarkers and wearable data, bringing aging assessment into ...
Janux Therapeutics (JANX) has drawn fresh attention after recent trading left the stock at $18.15, with returns over the past ...
Biotech's 2026 momentum hit an unexpected wall in the third quarter, and the culprit was not the quarter's string of high-profile clinical ...
Iambic Therapeutics (IAM Proposed) and City Therapeutics (CTY Proposed) are in the spotlight this week as the only two deals on the IPO Calendar so far. Both biotechs are set to g ...
Damora Therapeutics (DMRA) traded at $21.08 at the last close, drawing fresh attention to how this biopharmaceutical player’s ...
As a notorious night owl, it was already very early in the morning of October 5 when Karl Deisseroth, M.D., Ph.D., finally ...
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...
MedaSystems, a SaaS platform for managing Expanded Access, Post-Trial Access and Investigator-Initiated Study programs, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results